Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04643795 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
A Phase 1 study of Hepatic Impairment and Cirrhosis, Liver, sponsored by Madrigal Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
- 3
- Study locations
NCT04643795: Completed Phase 1 study of Hepatic Impairment and Cirrhosis, Liver, sponsored by Madrigal Pharmaceuticals.
NCT04643795 is a Phase 1 study of Hepatic Impairment and Cirrhosis, Liver that has completed, run by Madrigal Pharmaceuticals. The registered enrollment target is 87 participants, above the 35-participant average among 48 other Hepatic Impairment trials with a reported enrollment target (149% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04643795, a Phase 1 study of Hepatic Impairment and Cirrhosis, Liver, has completed, sponsored by Madrigal Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of MGL-3196 and its major metabolite (MGL-3623) following administration of multiple oral doses (QD x 6 days) in subjects with varying degrees of hepatic impairment (HI) compared to healthy matched control subjects with normal hepatic function, including a subset of NASH subjects.
Primary Outcome
Cmax after administration
Conditions Studied
Interventions
- DRUG MGL-3196
Study Locations (3)
Florida
- Madrigal Research Center - Orlando
Minnesota
- Madrigal Research Center - Saint Paul
Texas
- Madrigal Research Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2018-10-25 |
| Est. Completion | 2021-08-04 |
| Phase | Phase 1 |
What the finished NCT04643795 record still lists
NCT04643795 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, above the 35-participant average among 48 other Hepatic Impairment trials with a reported enrollment target (149% higher).
The record links to 3 conditions, with Hepatic Impairment appearing as the primary indexed condition, and to 1 intervention - of which MGL-3196 is the first listed.
NCT04643795 reports a single indexed study location in Florida, Minnesota, Texas.
Frequently Asked Questions
What is clinical trial NCT04643795 about?
NCT04643795 is a clinical study titled "Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects". The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of MGL-3196 and its major metabolite (MGL-3623) following administration of multiple oral doses (QD x 6 days) in subjects with varying degrees of hepatic impairment (HI) compared to healthy matched control subjec...
What is the current status of trial NCT04643795?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2018-10-25. Estimated completion is 2021-08-04.
What conditions does trial NCT04643795 study?
This clinical trial studies the following conditions: Hepatic Impairment, Cirrhosis, Liver, NASH - Nonalcoholic Steatohepatitis.
What interventions are being tested in trial NCT04643795?
The interventions under investigation include: MGL-3196 (DRUG).
Who is sponsoring clinical trial NCT04643795?
This trial is sponsored by Madrigal Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04643795 being conducted?
This trial has 3 study locations across Florida, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04643795's enrollment target sits among peer trials
87 4th of 48 higher than 45 of 48 other Hepatic Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatic Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
RECRUITING · Phase 1
-
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
RECRUITING · Phase 1
-
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
RECRUITING · Phase 1
-
A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI